BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 19846814)

  • 21. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.
    van Krieken JH
    J Hematop; 2010 Jun; 3(1):47-58. PubMed ID: 21633487
    [No Abstract]   [Full Text] [Related]  

  • 23. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
    Lin P; Owens R; Tricot G; Wilson CS
    Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Instability of immunophenotype in plasma cell myeloma.
    Cao W; Goolsby CL; Nelson BP; Singhal S; Mehta J; Peterson LC
    Am J Clin Pathol; 2008 Jun; 129(6):926-33. PubMed ID: 18480010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
    Raja KR; Kovarova L; Hajek R
    Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease monitoring in multiple myeloma.
    Davies FE; Rawstron AC; Owen RG; Morgan GJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.
    Bataille R; Jégo G; Robillard N; Barillé-Nion S; Harousseau JL; Moreau P; Amiot M; Pellat-Deceunynck C
    Haematologica; 2006 Sep; 91(9):1234-40. PubMed ID: 16956823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
    Yuan CM; Stetler-Stevenson M
    Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.